Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese & Iron Ores Management Change

Sandur Manganese completed G. P. Kundargi's second consecutive term as Independent Director on 11 November 2026. He was re-appointed as a Non-Executive Director from 12 November 2026, subject to shareholder approval.

Sandur Manganese & Iron Ores Annual General Meeting

Sandur Manganese & Iron Ores issued a postal ballot notice seeking shareholder approval to appoint G. P. Kundargi as Non-Executive Director. Remote e-voting runs from 9 November to 8 December 2026.

Sandur Manganese & Iron Ores Investor Presentation: Key Takeaways

Q2FY27 consolidated total income ₹1,519 Cr (+22% YoY), EBITDA ₹391 Cr (+37%), PAT ₹261 Cr (+88%). Margins expanding; diversifying into medtech and steel.

Sandur Manganese & Iron Ores Management Change

Sandur Manganese appointed G. P. Kundargi as a Non-Executive Director from 12 November 2026, subject to shareholder approval. He brings mining and metals experience.

Sandur Manganese & Iron Ores Q2 FY27 Results: Net Profit ₹261.2 Cr, Up 88.0% YoY

Sandur Manganese & Iron Ores Ltd reported revenue from operations of ₹1,506 Cr (+22.2% YoY) and net profit of ₹261.2 Cr (+88.0% YoY) for Q2 FY27.

Key figure

Net profit ₹261.2 Cr · +88.0% YoY

Sandur Manganese & Iron Ores Board Meeting Date

Sandur Manganese & Iron Ores will hold a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window is closed from 1 October 2026 until 48 hours after the meeting.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.